CM Life Sciences III

EQRx, Inc. is a pharmaceutical company, which engages in developing and delivering innovative medicines to patients having chronic conditions. The company was founded by Alexis A. Borisy, Sandra J. Horning, Robert M. Forrester, Peter Bach, and Melanie I. Nallicheri on August 26, 2019 and is headquartered in Cambridge, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

EQRx resets strategy to focus on high-value medicines and savings

EQRx is strategically focusing on high-value medicines and optimizing its portfolio for long-term growth and profitability.
Despite workforce reductions and strategic shifts, the company maintains a strong capital position and promising clinical data for Lerociclib.
Challenges lie in workforce reductions and revenue disruptions from terminating agreements, but opportunities exist in strategic acquisitions and new partnerships.
By balancing cost-cutting measures with growth initiatives, EQRx aims to enhance operational efficiency and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., Oct. 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced it will host a conference call and webcast on Thursday, November 10, 2022 at 8:00 a.m. ET to report its third quarter 2022 financial results and provide a business update.

EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022

EQRx, Inc. (NASDAQ:EQRX ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Neil Swami - Head, IR Melanie Nallicheri - President and CEO Jami Rubin - CFO Eric Hedrick - Chief Physician Executive Conference Call Participants Eric Percher - Nephron Research Chris Shibutani - Goldman Sachs Operator Good day. And thank you for standing by.

EQRx, Inc. (EQRX) CEO Melanie Nallicheri on Q2 2022 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today reported financial results for the second quarter ended June 30, 2022 and provided an overview of recent corporate progress.

EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress

CAMBRIDGE, Mass., Aug. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced a late-breaking oral presentation of updated data from the Phase 3 GEMSTONE-301 trial of sugemalimab in non-small cell lung cancer (NSCLC) at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC), taking place August 6 through August 9, 2022. These results are being featured in the WCLC press program.

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

Agriforce Growing Systems Ltd

Hecla Mining

Can these tips help your penny stock trading in June? The post 3 Tips and Tricks for Buying Penny Stocks in June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Tips and Tricks for Buying Penny Stocks in June

CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that the United Kingdom (U.K.)'s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for review the marketing authorization application (MAA) for aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI), in development for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced data from pivotal trials of sugemalimab, a PD-L1 inhibitor, and aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI), being presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022. The data further demonstrate the potential clinical benefit of these investigational medicines in non-small cell lung cancer (NSCLC) and of sugemalimab in relapsed or refractory (R/R) extranodal natural killer/T-cell lymphoma (ENKTL), a rare and aggressive form of non-Hodgkin lymphoma (NHL) that does not have approved treatment options in the U.S. These data will help support global regulatory submissions for sugemalimab and aumolertinib.

EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022

EQRx, Inc. (NASDAQ:EQRX ) Q1 2022 Results Conference Call May 13, 2022 8:00 AM ET Company Participants Neil Swami - Head-Investor Relations Melanie Nallicheri - President and Chief Executive Officer Eric Hedrick - Chief Physician Executive Jami Rubin - Chief Financial Officer Conference Call Participants Steve Scala - Cowen Eric Percher - Nephron Research Chris Shibutani - Goldman Sachs Operator Good day, and welcome to the EQRx First Quarter 2022 Financial Results Conference Call. At this time, all participants are on a listen-only mode.

EQRx, Inc. (EQRX) CEO Melanie Nallicheri on Q1 2022 Results - Earnings Call Transcript

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today reported financial results for the first quarter ended March 31, 2022 and provided an overview of recent corporate progress.

EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress

CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Friday, May 13, 2022 at 8:00 a.m. ET to report its first quarter 2022 financial results and provide a business update.

EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that new data on its lead oncology programs will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022.

EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

EQRx's (EQRX) CEO Melanie Nallicheri on Q4 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today reported financial results for the quarter and full year ended December 31, 2021 and provided an overview of recent corporate progress.

EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress

EQRx Inc (NASDAQ: EQRX), along with its partner CStone Pharmaceuticals has announced data from Phase 3 GEMSTONE-302 trial of sugemalimab plus chemotherapy as a first-line treatment for stage IV non-small cell lung cancer (NSCLC). The trial met the key secondary endpoint of prolonging overall survival with sugemalimab plus chemotherapy versus placebo plus chemotherapy.

EQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings

CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, along with its partner CStone Pharmaceuticals, today announced that sugemalimab plus chemotherapy demonstrated a statistically significant improvement in overall survival (OS) compared to placebo plus chemotherapy as a first-line treatment for patients with Stage IV non-small cell lung cancer (NSCLC) in the randomized, double-blind Phase 3 GEMSTONE-302 study. These data were reported after a planned interim analysis for OS, a key secondary endpoint of the study. These results build on previously presented positive data from the GEMSTONE-302 study, which met the primary endpoint of progression-free survival (PFS) and were recently published in The Lancet Oncology .1

Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced it has signed a non-binding memorandum of understanding (MOU) with Geisinger, a U.S.-based integrated delivery network. The MOU provides a roadmap for Geisinger and EQRx to enter into a commercial agreement that would give Geisinger's members and patients access to EQRx's pipeline of innovative medicines, contingent upon approval by the U.S. Food and Drug Administration (FDA). The MOU contemplates an expansion of the existing long-term strategic collaboration between the two organizations with a shared goal of bringing innovative therapies to the people Geisinger serves, in a financially sustainable way.

EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Lower Costs

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that Melanie Nallicheri, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 3:45 p.m. ET.

EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference

CM Life Sciences III - Unit

NEW YORK and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences III (Nasdaq: CMLT, CMLTW, CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, and EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced the completion of their business combination. The business combination was approved by CM Life Sciences III's stockholders at its special meeting held on December 16, 2021.

News for CM Life Sciences III Stock (EQRX)